Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819584 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.
J Neuroimmunol
November 2024
Department of Neurology, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Electronic address:
Article Synopsis
- The study examined how tacrolimus (TAC) affects CD4+ T cell subsets in 41 patients with AChR-MG over 12 weeks.
- Results showed that 27 patients responded positively to TAC treatment by exhibiting improved myasthenia gravis scores, while 14 did not respond.
- The findings suggest that TAC's clinical effectiveness is linked to its ability to lower Th17 and pathogenic Th17 cells, which may improve management of myasthenia gravis by modulating the immune response.
-mutation congenital myasthenic syndrome in late adolescence: Case report and review of the literature.
Heliyon
September 2023
Department of Neurology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Congenital myasthenia syndromes (CMS) are a heterogeneous group of hereditary disorders of the neuromuscular junction. The symptoms include fatigue, muscle weakness, ptosis, mastication or swallowing problem, respiratory distress. We present a 42-year-old male patient who was admitted with complaints of paroxysmal limb weakness for 25 years and got repeated apnea crisis due to using AchE inhibitors.
View Article and Find Full Text PDFSurvival, Prognosis, and Clinical Feature of Refractory Myasthenia Gravis: a 15-year Nationwide Cohort Study.
J Korean Med Sci
October 2021
Department of Pharmacy, School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
Background: Myasthenia gravis (MG) is a rare classic autoimmune disease where immunosuppressant therapies have been successful to reduce MG attributable mortality fairly well. However, patients with refractory MG (rMG) among the actively treated MG (aMG) are nonresponsive to conventional therapy and display high disease severity, which calls for further research. We aimed to determine survival, prognosis, and clinical feature of patients with rMG compared to non-rMG.
View Article and Find Full Text PDFBortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.
Inflammopharmacology
October 2021
Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Autoimmune diseases (ADs) are conditions in which the immune system cannot distinguish self from non-self and, as a result, tissue injury occurs primarily due to the action of various inflammatory mediators. Different immunosuppressive agents are used for the treatment of patients with ADs, but some clinical cases develop resistance to currently available therapies. The proteasome inhibitor bortezomib (BTZ) is an approved agent for first-line therapy of people with multiple myeloma.
View Article and Find Full Text PDFNonresponsive Myasthenia is Suspicious for Congenital Myasthenic Syndrome or Myopathy.
Innov Clin Neurosci
October 2020
Klinik Landstrasse, Messerli Institute in Vienna, Austria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!